KEYNOTE-585: Phase 3 study of chemotherapy (chemo) + pembrolizumab (pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G/GEJ) cancer.

Authors

null

Yung-Jue Bang

Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Republic of (South), Korea

Yung-Jue Bang , Eric Van Cutsem , Charles S. Fuchs , Atsushi Ohtsu , Josep Tabernero , David H. Ilson , Woo Jin Hyung , Vivian E. Strong , Thorsten Oliver Goetze , Takaki Yoshikawa , Laura H. Tang , Peggy May Tan Hwang , Kohei Shitara

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT03221426

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS4136)

DOI

10.1200/JCO.2018.36.15_suppl.TPS4136

Abstract #

TPS4136

Poster Bd #

322b

Abstract Disclosures